Candida infections in children treated with conventional chemotherapy for solid tumors (transplant recipients excluded): The Institut Gustave Roussy Pediatrics Department experience

Abstract

Candidemia is a rare but severe complication in pediatric oncology. Even if the prognosis is better in children than in adults, Candida septicemia remains of great concern since a high percentage of these infections result in visceral dissemination and mortality is still elevated.

Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy

“…In autopsied cancer patients, invasive candidosis is found in 7% up to 30% of patients 61,62 . After intensive chemotherapy for solid tumours, candidaemia is found in 0% to 5% 51,63–66 …”

“…61,62 After intensive chemotherapy for solid tumours, candidaemia is found in 0% to 5%. 51,[63][64][65][66] Epidemiological trends may differ between European countries. Whereas the incidence and species distribution in Switzerland did not change between 1991 and 2000, an increasing incidence has been described in Scandinavian countries (from 1.7 to 2.2 cases per 100 000 inhabitants in Finland and from 6.5 to 15.6 cases in Norway) without a shift in the relative amount of different Candida species.…”

Polysaccharide-rich fraction of Agaricus brasiliensis enhances the candidacidal activity of murine macrophages

“…Candida albicans is a very common dimorphic fungus that can cause opportunistic infection and, although most people are resistant to this agent, candidiasis is the most frequent fungal infection among immune depressed individuals such as diabetes (Donders 2002), cancer (Ridola et al 2004) and HIV patients (Klein et al 1984). Resistance to C. albicans depends on a coordinated action of innate and adaptive immune defenses, a process to which phagocytosis by granulocytes and macrophages is crucial.…”

Breakthrough invasive candidiasis in pediatric patient with Ewing’s sarcoma: dinical case report and literature review

“…В исследовании V. Ridola и соавт. имеются указания на более короткий период от начала противоопухолевой терапии до развития ИК, составляющий 2 мес [17].…”